Association of Childbirth Pain with Postnatal Depressive and Anxiety Disorders in Nulliparous Parturients: A Prospective Study

Abstract

Purpose

There is limited knowledge on the relationship between postnatal depression and childbirth pain characteristics associated with childbirth. We investigated whether the characteristics of childbirth pain, as assessed by Short-form-McGill Pain Questionnaire-2 (SF-MPQ-2), were associated with postnatal anxiety and depressive disorders.

Patients and Methods

Nulliparous parturients who received labor epidural analgesia (LEA) and delivered in our institution were invited to have a Mini-International Neuropsychiatric Interview (MINI) assessment following their 5–9 weeks post-delivery follow-up phone survey of a larger study. Parturients’ demographics, pre-delivery questionnaires on pain and psychological vulnerabilities, LEA data, maternal and neonatal outcomes, postnatal follow-up survey on pain and psychological vulnerabilities, pain and breastfeeding were collected accordingly. The primary outcome was the binary variable (yes/no) of the presence of postnatal depression and/or anxiety disorders based on the post-delivery MINI assessment.

Results

Among the 107 parturients who participated in the post-delivery MINI assessment, a total of 40 (42.5%) patients were found to have postnatal anxiety and depressive disorders. A greater pre-delivery SF-MPQ-2 neuropathic pain mean subscale score (adjusted odds ratio (OR) 1.32, 95% CI 1.00–1.73, p=0.0482) and greater post-delivery Edinburgh Postnatal Depression Scale (EPDS) at 5–9 weeks post-delivery (adjusted OR 1.30, 95% CI 1.13–1.50, p=0.0002) were independently associated with the presence of postnatal anxiety and/or depressive disorders (receiver operating characteristic (ROC) = 0.7489).

Conclusion

Patients with greater pre-delivery neuropathic pain and higher EPDS scores at 5–9 weeks post-delivery are more likely to have postnatal depression and/or anxiety disorders, suggesting possible associations between pain and psychological vulnerability in the development of postnatal mental disorders.

Keywords:

• neuropathic pain
• postnatal depression
• anxiety
• pain vulnerability

Introduction

Postnatal depression (PND) is associated with significant long-term psychological and socio-economic implications in mothers, their offspring, and families. The reported incidence of PND after childbirth may vary from 27% to 32% in the Asian population,^1–4 and well-established risk factors of PND include but are not limited to pain severity, analgesic technique and psychological susceptibility during childbirth and delivery.^5–7

Anxiety disorders are phenomenologically heterogeneous in nature, and these can be categorized into several groups predominantly characterized by: i) anxiety (generalized anxiety disorder (GAD)), ii) fear-related obsessional thoughts and behavioral compulsions (obsessive-compulsive disorder (OCD)), and iii) fear (phobias, panic disorder, etc.).⁸ Similar to PND, postnatal anxiety may lead to detrimental maternal and neonatal outcomes; however, it has received less attention despite being a common co-morbidity with depression.⁹ Postnatal anxiety has been associated with disengaged, negative and over-controlling maternal and parenting behaviors, highlighting the need to inform screening and treatment efforts.^9,10

Neuropathic pain, as defined by the International Association for the Study of Pain (IASP), is “the pain caused by a lesion or dysfunctional nervous system”.¹¹ Neuropathic pain has been reported during the peripartum and postpartum periods, and could reduce functional status and health-related quality of life in pregnant women.¹² Interestingly, both depression and anxiety are well-known co-morbidities with neuropathic pain, especially in chronic pain patients. A recent animal study showed that neuropathic pain state may promote adaptations in gene expressions responsible for anxiety and depressive symptoms.¹³ While pain elements, such as breakthrough pain during labor epidural analgesia (LEA) and acute pain after childbirth have been found to be significantly associated with increased Edinburgh Postnatal Depression Scale (EPDS) scores, there is limited knowledge on the association of specific childbirth pain characteristics on postnatal mental disorders.^7,14

In this study, we investigated whether characteristics of childbirth pain, especially in the context of neuropathic pain, were associated with postnatal anxiety and depressive disorders. We also investigated the association of perinatal factors (demographic, pain, LEA, maternal and neonatal outcomes, psychological) with presence of postnatal anxiety and/or depressive disorders.

Patients and Methods

Patient Recruitment

This was a prospective cohort study from a secondary analysis of a randomized controlled trial that investigated the performance of different regimens for LEA maintenance. Approval was obtained from SingHealth Centralized Institutional Review Board (2014/670/D; 2018/3128) and registered at ClinicalTrials.gov (NCT02278601). Written informed consent was obtained prior to any study activity. This study adheres to the applicable Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines.

We recruited parturients in KK Women’s and Children’s Hospital, Singapore, between January 2015 and March 2019. We included nulliparous parturients aged 21–50 years old, ≥36 gestational weeks with singleton pregnancy, and in early labor (cervical dilation <5 cm) requesting LEA. Parturients with non-cephalic fetal presentation, obstetric complications and contraindications to LEA, received parenteral opioids within two hours prior to LEA initiation or suspected inadvertent dural puncture during LEA initiation, were excluded.

All LEA were performed following descriptions as stated in Zeng et al.⁷ Once the patient received LEA and felt comfortable (ie not in pain or in distress), the following questionnaires (English or Chinese) were self-administered before delivery:

1. Short-form-McGill Pain Questionnaire-2 (SF-MPQ-2) is designed specifically and validated in the context of pain syndromes to differentiate different qualities of neuropathic and non-neuropathic pain in four subscales: continuous pain (throbbing pain, cramping pain, gnawing pain, aching pain, heavy pain, tender), intermittent pain (shooting pain, stabbing pain, splitting pain, electric-shock pain, piercing), neuropathic pain (hot-burning pain, cold-freezing pain, pain caused by light touch, itching, tingling or pins and needles, numbness), and affective descriptors (tiring-exhausting, sickening, fearful, punishing-cruel).¹⁵ In this study, SF-MPQ-2 questionnaire was administered to measure pre-delivery neuropathic and non-neuropathic pain on an 11-point scale, with 0 being none and 10 being the worst possible intensity. The four subscale scores are calculated as the mean of items in each subscale, whereas the total score is the mean of all 22 items;

2. EPDS, a 10-item validated self-reported screening tool for antenatal/postnatal depression with a total score of 0–30. With a cut-off score of 10, this would encompass a range of probable postnatal depressive states;^16,17

3. EuroQol-5-dimension-3-level (EQ-5D-3L), a widely used instrument to measure health-related quality of life;¹⁸

4. Pain Catastrophizing Scale (PCS), a validated 13-item instrument to evaluate the processes of negative thoughts when encountering actual/anticipated pain or painful experiences. A cut-off score of 25 was used based on previous studies on intrapartum parturients;^7,19

5. Cohen’s Perceived Stress Scale (PSS), a 10-item questionnaire to quantify the perception of stress. We used a cut-off score of 20 as suggested by previous studies, which illustrated good internal consistencies (Cronbach’s alpha 0.78–0.91);^20,21

6. Spielberger’s State Trait Anxiety Inventory (STAI) that comprises 40 items to assess transient anxiety (state) during questionnaire administration, the dispositional anxiety (trait) and anxiety in general.²² In this study, STAI and its subscales were measured as continuous variables as there are no reliable cut-off scores established thus far in the perinatal population.²³ Nevertheless, STAI is still considered the most robust and specific instrument to measure perinatal anxiety as compared with other anxiety measures.²³

Childbirth processes for all parturients were managed by a team of multidisciplinary staff including obstetricians, nurses and midwives, with each patient being in a single-room delivery suite in our institution. Parturients’ demographics (BMI, race, age, gravida, gestation, indirect morbidities, drug allergy), LEA data (pain scores-numerical rating scale (NRS) 0–10), number of LEA attempts, total time taken for LEA initiation, number of anesthetist(s), depth of space, loss of resistance, catheter in space, incidence of breakthrough pain, post-LEA complications, satisfaction with LEA), maternal and neonatal outcomes (use of oxytocin, labor onset, mode of delivery, duration of labor, infant body weight and length, infant sex and head circumference) were collected. Postnatal follow-up survey was conducted via phone by the study team members at 5–9 weeks post-delivery to administer questionnaires on EPDS, EQ-5D-3L, STAI, and questions pertaining to pain and breastfeeding.

MINI Assessment

During the 5–9 weeks post-delivery follow-up phone survey, women were invited to be interviewed by the study's research coordinator, who was trained and supervised by investigators (T Chua, H Chen) in the use of the Mini-International Neuropsychiatric Interview (MINI). The MINI is a brief, structured psychiatric interview developed to assess the most common psychiatric disorders as listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R, DSM-IV, DSM-5, and International Classification of Diseases-10th revision (ICD-10).²⁴ Based on the diagnostic categories, the MINI may be divided into modules for further assessment, of which five modules were used in the present study: major/minor depressive disorder, GAD, panic disorder, agoraphobia, and OCD to encompass the possible co-morbidity of both depression and anxiety in postpartum women.

Statistical Analysis

The study's goal was to understand the childbirth pain experience of women with defined clinical postnatal depression and/or anxiety disorders, rather than general measures of depressive symptoms. Hence, the primary outcome was defined as the presence of postnatal depression and/or anxiety disorders based on the post-delivery MINI assessment (including any anxiety disorders in GAD, depressive disorders that affected daily life activities, lifetime panic disorder, obsession/compulsions, and/or current agoraphobia) and was treated as binary data with status “yes” or “no”. The primary objective was to evaluate the association between pre-delivery neuropathic pain, as measured by the mean of six items in SF-MPQ-2 neuropathic subscale, and the presence of postnatal anxiety and/or depressive disorders.

The continuous and categorical variables were summarized as mean ± standard deviation (SD), median [interquartile range (IQR)] or frequency (proportion) where appropriate. Univariate and multivariable logistic regression analyses were performed to find association between postnatal anxiety and/or depressive disorders and independent variables. Quantitative association from logistic regression was expressed as odds ratio (OR) with corresponding 95% confidence interval (95% CI). Variables, with P < 0.10 in the univariate logistic regression were chosen for the multivariable model, and a stepwise variable selection method was used to finalize the multivariable model. Area under the curve (AUC) from receiver-operating characteristics (ROC) based on the final multivariable model was reported to check the robustness and predictive ability of the model. All tests were two-sided, with P < 0.05 considered as statistically significant. SAS software (version 9.4, SAS Institute; North Carolina, USA) was used for all analyses.

Results

One hundred and seven women were invited to participate in the MINI assessment that took place after the 5–9 weeks post-delivery phone follow-up (median [IQR] duration between post-delivery follow-up and MINI: 23 [24] days) with no drop-out. There were 67 (57.5%) without and 40 (42.5%) patients with postnatal anxiety and depressive disorders (Figure 1). The study cohort had a mean age of 29.5 ± 4.3 years old (age range: 21 to 43 years old), a mean BMI of 27.9 ± 4.7 kg/m², and a mean gestation of 37.6 ± 1.8 weeks. There were no significant differences in demographic characteristics (Table 1), LEA data (Table 2) nor maternal and neonatal outcomes (Table 3) between those with and without postnatal anxiety and/or depressive disorders. We also found no significant univariate association (P < 0.05) in the SF-MPQ-2 subscales and postnatal anxiety and/or depressive disorders (Table 2). A separate analysis on SF-MPQ-2 subscales showed that they had no significant associations with postnatal anxiety and postnatal depressive disorders, respectively (Supplementary Table 1).

Figure 1 Study flowchart.

Abbreviations: EPDS, Edinburgh Postnatal Depression Scale; EQ-5D-3L, EuroQol-5-dimension-3-level; PCS, Pain Catastrophizing Scale; PSS, Cohen’s Perceived Stress Scale; SF-MPQ-2, Short-form-McGill Pain Questionnaire-2; STAI, Spielberger’s State Trait Anxiety Inventory.

Table 1 Demographic Characteristics in Patients with or without Postnatal Anxiety and/or Depressive Disorders

Parameters	Without Postnatal Anxiety and/or Depressive Disorders (n=67)	With Postnatal Anxiety and/or Depressive Disorders (n=40)	Unadjusted OR (95% CI)	P-value
Age (years)	29.5 ± 4.1	29.6 ± 4.5	1.00 (0.92, 1.10)	0.8921
Race				0.1870^a
Chinese	43 (65.2)	18 (45.0)	Reference	–
Malay	10 (15.2)	9 (22.5)	2.15 (0.75, 6.18)	0.6106
Indian	5 (7.6)	3 (7.5)	1.43 (0.31, 6.64)	0.7353
Others	8 (12.1)	10 (25.0)	2.99 (1.02, 8.79)	0.2014
Weight at first prenatal visit	57.2 ± 9.6	61.4 ± 15.1	1.03 (1.00, 1.07)	0.0854
Weight at term (kg)	70.1 ± 11.4	72.6 ± 13.8	1.06 (0.98, 1.05)	0.3231
Height (cm)	158.7 ± 6.5	161.1 ± 6.1	1.06 (1.00, 1.13)	0.0620
BMI at term (kg/m^2)	27.9 ± 4.3	27.9 ± 5.3	1.00 (0.92, 1.09)	0.9950
Gravida	1.2 ± 0.6	1.4 ± 0.7	1.75 (0.91, 3.37)	0.0967
Gestational age (weeks)	37.7 ± 1.8	37.5 ± 1.8	0.98 (0.92, 1.04)	0.4679
Indirect morbidities				0.5596^a
Nil	56 (84.8)	31 (77.5)	Reference	–
Diabetes mellitus	0	4 (10.0)	16.14 (0.60, 435.88)	0.0981
Gastrointestinal tract	1 (1.5)	1 (2.5)	1.79 (0.11, 29.67)	0.6835
Respiratory	2 (3.0)	1 (2.5)	1.08 (0.21, 3.40)	0.9517
Others	7 (10.6)	3 (7.5)	0.84 (0.21, 3.40)	0.8035
Drug allergy	14 (21.2)	7 (17.5)	0.79 (0.29, 2.16)	0.6425

Notes: Values are expressed in mean ± standard deviation (SD) or number (%). ^aType 3 p – value (To indicate if variable in overall has any association with outcome).

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio.

Table 2 Pain Characteristics in Patients with or without Postnatal Anxiety and/or Depressive Disorders

Parameters	Without Postnatal Anxiety and/or Depressive Disorders (n=67)	With Postnatal Anxiety and/or Depressive Disorders (n=40)	Unadjusted OR (95% CI)	P-value
Pre-delivery and delivery
SF-MPQ-2 Continuous pain subscale (0–10)	2.8 ± 2.2	2.6 ± 2.2	0.96 (0.80, 1.15)	0.6666
SF-MPQ-2 Intermittent pain subscale (0–10)	1.7 ± 2.1	1.9 ± 2.4	1.05 (0.88, 1.26)	0.5678
SF-MPQ-2 Neuropathic pain subscale (0–10)	1.6 ± 1.5	2.2 ± 1.8	1.28 (1.00, 1.63)	0.0529
SF-MPQ-2 Affective descriptors subscale (0–10)	2.2 ± 1.9	2.4 ± 2.2	1.05 (0.87, 1.28)	0.6090
SF-MPQ-2 total (0–10)	2.0 ± 1.6	2.3 ± 2.0	1.08 (0.86, 1.35)	0.5090
Pre-block pain score (0–10)	6.3 ± 2.6	6.9 ± 2.6	1.11 (0.94, 1.31)	0.2231
Number of LEA attempts	1.3 ± 0.6	1.4 ± 0.9	1.31 (0.76, 2.24)	0.3303
Total time taken for LEA initiation (min)	8.2 ± 4.4	9.3 ± 8.7	1.03 (0.96, 1.09)	0.4119
Number of anesthetist(s)	1.1 ± 0.3	1.1 ± 0.3	1.36 (0.34, 5.38)	0.6652
Depth of space (cm)	4.7 ± 0.9	4.8 ± 1.1	1.08 (0.72, 1.61)	0.7057
Loss of resistance - saline	65 (98.5)	39 (97.5)	1.67 (0.10, 27.41)	0.7207
Catheter in space (cm)	4.8 ± 1.4	4.7 ± 0.9	0.90 (0.59, 1.33)	0.5692
Breakthrough pain	11 (16.7)	10 (25.0)	1.67 (0.41, 6.65)	0.2995
Post-LEA complications^a	4 (6.0)	4 (10.0)	1.75 (0.41, 7.42)	0.4479
Patient satisfaction with LEA	90.4 ± 8.4	90.4 ± 10.5	1.00 (0.96, 1.04)	0.9646
5–9 weeks post-delivery
Sub-acute pain lasting for 4 weeks or more	4 (6.0)	3 (7.7)	1.31 (0.28, 6.20)	0.7313
Pain at post-delivery period affects sleep	10 (14.9)	12 (30.0)	2.3 (0.87, 6.09)	0.0936
Mood affected by post-delivery pain	12 (17.9)	16 (40.0)	2.93 (1.17, 7.33)	0.0214
Have seen a doctor because of post-delivery pain	3 (4.5)	6 (15.0)	3.53 (0.82, 15.16)	0.0894
Took pain medication after delivery	23 (34.3)	12 (30.0)	0.72 (0.30, 1.72)	0.4563
Have problems with post-delivery pain anywhere on body other than scar, wound or abdomen	20 (29.9)	18 (46.2)	2.01 (0.89, 4.57)	0.0936

Notes: Values are expressed in terms of mean ± SD. ^aThere were 2 patients with backache, 1 patient with urinary retention and 1 with other complication (not specified) in those without postnatal anxiety and/or depressive disorders. Among those having postnatal anxiety and/or depressive disorders, 2 patients were found to have post-LEA backache, 1 patient with neural deficit and 1 with urinary retention.

Abbreviations: CI, confidence interval; OR, odds ratio; LEA, labor epidural analgesia; SF-MPQ-2, Short-form-McGill Pain Questionnaire-2.

Table 3 Maternal and Neonatal Characteristics in Patients with or without Postnatal Anxiety and/or Depressive Disorders

Parameters	Without Postnatal Anxiety and/or Depressive Disorders (n=67)	With Postnatal Anxiety and/or Depressive Disorders (n=40)	Unadjusted OR (95% CI)	P-value
Delivery
Use of oxytocin	21 (35.0)	9 (30.0)	0.80 (0.31, 2.05)	0.6356
Mode of labor onset				0.6521^a
Prostin	21 (31.8)	10 (25.0)	Reference	–
Spontaneous	30 (45.5)	22 (55.0)	1.54 (0.61, 3.91)	0.3642
Artificial rupture of membranes	15 (22.7)	8 (20.0)	1.12 (0.36, 3.51)	0.8458
Duration of first stage of labor (min)	475.0 ± 276.2	476.7 ± 297.4	1.00 (1.00, 1.00)	0.9749
Duration of second stage of labor (min)	65.1 ± 59.6	62.3 ± 53.2	1.00 (0.99, 1.00)	0.8095
Infant body weight (kg)	3.2 ± 0.4	3.1 ± 0.4	0.77 (0.25, 2.40)	0.6358
Infant body length (cm)	49.1 ± 2.0	49.4 ± 1.8	1.09 (0.89, 1.35)	0.4084
Head circumference (cm)	33.5 ± 1.3	33.4 ± 1.3	0.96 (0.70, 1.30)	0.7710
Gender
Male	34 (51.5)	21 (52.5)	Reference	–
Female	32 (48.5)	19 (47.5)	1.04 (0.47, 2.28)	0.9217
Mode of delivery				0.7315^a
Normal vaginal delivery	37 (56.1)	24 (60.0)	Reference	–
Instrumental (Vacuum/ Forceps)	14 (21.2)	6 (15.0)	0.66 (0.22, 1.96)	0.4544
Cesarean delivery	15 (22.7)	10 (25.0)	1.03 (0.40, 2.66)	0.9550
5–9 weeks post-delivery
Rating of delivery experience				0.0407^a
Satisfactory	28 (41.8)	17 (43.6)	Reference	–
Extremely/ very satisfactory	37 (55.2)	15 (38.5)	0.67 (0.29, 1.56)	0.3520
Extremely/ very unsatisfactory	2 (3.0)	7 (17.9)	5.76 (1.07, 31.01)	0.0414
Received help from lactation consultant during stay in hospital on breastfeeding or giving breast milk to baby	39 (58.2)	16 (40.0)	0.48 (0.22, 1.06)	0.0702
Still breastfeeding or giving breast milk to baby	59 (88.1)	29 (74.4)	0.39 (0.14, 1.10)	0.0759
Direct breastfeeding baby in the last 24 hours	46 (68.7)	21 (52.5)	0.51 (0.23, 1.13)	0.0967
Fed expressed breast milk through bottle to baby in the last 24 hours	38 (56.7)	16 (40.0)	0.51 (0.23, 1.13)	0.0962
Fed breast milk to baby in the last 24 hours	57 (85.1)	28 (70.0)	0.41 (0.16, 1.06)	0.0663

Notes: Values are expressed in mean ± standard deviation (SD) or number (%). ^aType 3 p – value.

On univariate analysis, pre-delivery EPDS score was greater in those with postnatal anxiety and/or depressive disorders (7.6 ± 3.8) as compared with those without (5.8 ± 3.7; OR 1.13, 95% CI 1.02–1.26, p=0.0223) (Table 4). A pre-delivery PSS score of ≥20 was found to be associated with presence of postnatal anxiety and/or depressive disorders (OR 2.74, 95% CI 1.07–7.05, p=0.0359). At 5–9 weeks post-delivery follow-up phone survey, all measured psychological characteristics were significantly associated with postnatal anxiety and/or depressive disorders: EPDS (OR 1.29, 95% CI 1.13–1.48, p=0.0003), EQ-5D-3L health status (OR 0.92, 95% CI 0.87–0.97, p=0.0038), and STAI state anxiety (OR 1.08, 95% CI 1.03–1.13, p=0.0020) (Table 4).

Table 4 Psychological Characteristics in Patients with or without Postnatal Anxiety and/or Depressive Disorders

Parameters	Without Postnatal Anxiety and/or Depressive Disorders (n=67)	With Postnatal Anxiety and/or Depressive Disorders (n=40)	Unadjusted OR (95% CI)	P-value
Pre-delivery
EPDS total score (0–30)	5.8 ± 3.7	7.6 ± 3.8	1.13 (1.02, 1.26)	0.0223
EPDS score ≥ 10	11 (16.4)	11 (27.5)	1.93 (0.75, 4.99)	0.1739
EQ-5D-3L health status (0–100)	72.2 ± 17.4	76.8 ± 14.3	1.02 (0.98, 1.06)	0.3130
PCS rumination (0–16)	8.4 ± 4.7	8.3 ± 4.5	1.00 (0.92, 1.09)	0.9361
PCS magnification (0–12)	4.2 ± 2.7	4.9 ± 3.0	1.09 (0.95, 1.26)	0.2243
PCS helplessness (0–24)	10.4 ± 6.3	9.6 ± 5.5	0.98 (0.92, 1.05)	0.5393
PCS total score (0–52)	22.9 ± 12.6	22.8 ± 11.8	1.00 (0.97, 1.03)	0.9589
PCS score ≥ 25	31 (46.3)	17 (42.5)	0.86 (0.39, 1.89)	0.7046
PSS total score (0–40)	14.4 ± 5.4	16.4 ± 5.2	1.08 (1.00, 1.16)	0.0614
PSS score ≥ 20	10 (14.9)	13 (32.5)	2.74 (1.07, 7.05)	0.0359
STAI state anxiety (20–80)	34.9 ± 10.0	37.4 ± 11.9	1.02 (0.99, 1.06)	0.2377
STAI trait anxiety (20–80)	35.3 ± 9.1	37.8 ± 9.8	1.03 (0.99, 1.07)	0.1833
STAI total score (40–160)	70.1 ± 18.3	75.2 ± 20.6	1.01 (0.99, 1.04)	0.1894
5–9 weeks post-delivery
EPDS total score (0–30)	1.7 ± 2.1	4.6 ± 4.7	1.29 (1.13, 1.48)	0.0003
EPDS score ≥ 10	0	10 (25.6)	48.03 (2.38, 971.21)	0.0116
EQ-5D-3L health status (0–100)	83.9 ± 14.3	69.3 ± 20.0	0.92 (0.87, 0.97)	0.0038
STAI state anxiety (20–80)	28.0 ± 7.5	34.1 ± 10.7	1.08 (1.03, 1.13)	0.0020
STAI trait anxiety (20–80)	31.3 ± 8.7	34.9 ± 10.6	1.04 (1.00, 1.09)	0.0619
STAI total score (40–160)	59.3 ± 15.3	69.0 ± 19.8	1.03 (1.00, 1.06)	0.0081

Notes: Values are expressed in mean ± standard deviation (SD) or number (%).

Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale; EQ-5D-3L, EuroQol-5-dimension-3-level; OR, Odds ratio; PCS, Pain Catastrophizing Scale; PSS, Cohen’s Perceived Stress Scale; STAI, Spielberger’s State Trait Anxiety Inventory.

Follow-up survey at 5–9 weeks post-delivery demonstrated that mood affected by post-delivery pain (OR 2.93, 95% CI 1.17–7.33, p=0.0214) (Table 2) and unsatisfactory delivery experience (OR 5.76, 95% CI 1.07–31.01, p=0.0414) (Table 3) was significantly associated with presence of postnatal anxiety and/or depressive disorders. There were no significant associations found of breastfeeding with postnatal anxiety and/or depressive disorders (Table 3).

A greater pre-delivery SF-MPQ-2 neuropathic pain mean subscale score (adjusted OR 1.32, 95% CI 1.00–1.73, p=0.0482) and greater post-delivery EPDS at 5–9 weeks post-delivery (adjusted OR 1.30, 95% CI 1.13–1.50, p=0.0002) were independently associated with the presence of postnatal anxiety and/or depressive disorders (Figure 2). The AUC of ROC based on the multivariable analysis was 0.7489.

Figure 2 Receiver-operating characteristic (ROC) of the multivariable model.

Abbreviation: AUC, area under curve.

Discussion

Women with greater pre-delivery neuropathic pain, as determined by the neuropathic subscale of SF-MPQ-2, and higher EPDS scores at 5–9 weeks post-delivery were more likely to have postnatal anxiety and/or depressive disorders categorized as major/minor depressive disorder, GAD, panic disorder, agoraphobia, and OCD as listed in the MINI assessment.

Neuropathic pain complaints, such as carpal tunnel syndrome, meralgia paresthetica, and scar pain associated with previous cesarean delivery, are associated with pregnancy.²⁵ During labor, neuropathic pain may arise from direct pressure on the lumbosacral plexus, which is left exposed to the pelvic area, and the pain may usually be resolved after the childbirth process.²⁵ Previous studies have suggested an association between the intensity of labor pain and PND development;^26,27 a prospective observational study in 72 women showed that increased pain at each perinatal time point (pre-delivery, labor, post-delivery) was independently associated with increased EPDS scores at 6 weeks after delivery. However, whether the pain syndrome is of neuropathic nature is unknown.²⁷ The SF-MPQ-2 was used in Cesarean delivery to evaluate for post-delivery chronic neuropathic pain; however, there is limited information on its use in those undergoing labor process.²⁸ We demonstrated that pre-delivery neuropathic pain, as measured by SF-MPQ-2, was associated with postnatal anxiety and/or depressive disorders. To our knowledge, this association is relatively unexplored and suggests that a closer look based on pathophysiology of pain characteristics may be important, particularly in relation to postnatal mental health status.

While EPDS was previously validated as a screening tool for depression and anxiety with regard to MINI assessment, EPDS has demonstrated high sensitivity (82–84%) for detecting MINI mental disorders.²⁹ While it is possible to use EPDS as a preliminary screening tool in busy maternal-fetal units, further psychiatric assessment via DSM-5, the gold standard for diagnosing PND, is recommended. Our previous study showed that EPDS may yield false positives and has low positive predictive value (PPV) for both major and any depression (23.68% and 36.84%, respectively) in high-risk pregnancies, and this suggests that the clinical use of the EPDS is more suitable for screening, than being used as a confirmatory tool.²⁹ Hence, EPDS should retain its clinical utility as a screener to identify women requiring further assessment. In the absence of clinical diagnostic assessment, a structured DSM-5 interview, such as the MINI, can help to further assess the specific diagnostic conditions in those having elevated EPDS scores.²⁹

Rosseland et al demonstrated that negative birth experience was significantly associated with PND at 8 weeks post-delivery.³⁰ Conversely, previous study compared the incidence of PND among those who received LEA, and found that there was no difference in the PND rate between those who were satisfied with LEA and those among women who were not satisfied with LEA.³¹ This is in line with our findings where a significant association was found between overall delivery experience and postnatal anxiety/depressive disorders, but not LEA satisfaction, suggesting that there could be potential confounders other than childbirth pain and treatment for childbirth pain that may affect the maternal outcomes.

Increased stress during labor is known to have adverse maternal consequences, including prolonged labor, reduced uterine contractions, and delayed wound healing.³² In the postpartum setting, Razurel et al showed a significant positive correlation between perceived stress and postnatal anxiety and depressive symptoms. However, we found that pre-delivery PSS≥20 was a significant univariate factor but not an independent risk factor in the multivariable model.³³ This may be attributed to the use of different questionnaire (Antenatal Perceived Stress Inventory (APSI)), smaller sample size in our study, or the utilization of a different cut-off that may differ in different cultural and obstetric practice context.³³ Similarly, Grant et al demonstrated that an increase in both pre-delivery (37 gestational weeks) and 32 weeks post-delivery STAI trait anxiety was associated with postnatal depressive and anxiety disorders, but not pre-delivery state anxiety.³⁴ In this study, however, we did not find a significant association between pre-delivery anxiety and postnatal mental disorders, and only STAI state anxiety was significant with postnatal depression/anxiety disorders at 5–9 weeks post-delivery period. The differing findings could be related to different patient demographics and different time-point on follow-up, but possibly due to this study recruiting women who all received LEA. To date, there are only a few anxiety-related instruments (eg, Pregnancy-related Anxiety Scale (PAS), Perinatal Anxiety Screening Scale (PASS)) specifically designed for pregnant population and one for postnatal anxiety (Postpartum Specific Anxiety Scale (PSAS)). Hence, further validation is required for the clinical relevance of these instruments.^35–37

There were several limitations in this study. First, the inclusion criteria on nulliparous Asian parturients may result in different perceptions and psychological characteristics, which may not be generalized to other obstetric populations. Secondly, we recruited only parturients who requested LEA, and hence would not be able to provide generalized data for those who did not opt for LEA. The intended study design, however, allowed a more homogenous cohort to reduce potential confounding factors and evaluate independent risk factors. Thirdly, we recruited only English and/or Chinese-speaking patients for the questionnaire administration; language and cultural differences may influence the findings. Factors such as education, income, occupation, social/partner support, motherhood transition, and pain history that were previously associated with postnatal depression/anxiety disorders were also not taken into account.^9,38,39 Fourthly, anxiety and depression often co-exist in postpartum women, as unpredictable challenges are associated with anxiety, and difficulties with coping are associated with depressive symptoms. We were unable to examine the potential reverse causality between anxiety and depression as there were only two time points of measure. The sample size was limited and not able to control for the impact of depression on anxiety and vice versa. Finally, we only included a few types of anxiety (GAD, panic disorder, agoraphobia) disorders during the MINI assessment since they are more prevalent in pregnant patients. Future studies may include investigating other types of mental disorders, eg, post-traumatic stress disorder for more comprehensive analyses.

Conclusion

Women with greater pre-delivery neuropathic pain and higher EPDS scores at 5–9 weeks post-delivery were associated with an increased risk of postnatal depression/anxiety disorders. This suggests that pain and psychological vulnerability are important factors associated with postnatal mood disorders. Future studies to validate the above findings are needed to confirm the suggested model and refine the role of neuropathic pain in childbirth, so that risk stratification and early interventions can be instituted to reduce maternal postnatal depression and anxiety.

Abbreviations

APSI, Antenatal Perceived Stress Inventory; AUC, area under the curve; BMI, body mass index; CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale; EQ-5D-3L, EuroQol-5-dimension-3-level; GAD, Generalized anxiety disorder; IASP, International Association for the Study of Pain; LEA, labor epidural analgesia; OCD, obsessive-compulsive disorder; OR, odds ratio; MINI, Mini-International Neuropsychiatric Interview; NRS, numerical rating scale; PAS, Pregnancy-related Anxiety Scale; PASS, Perinatal Anxiety Screening Scale; PCS, Pain Catastrophizing Scale; PND, postnatal depression; PPV, positive predictive value; PSAS, Postpartum Specific Anxiety Scale; PSS, Perceived Stress Scale; ROC, receiver operating characteristic; SD, standard deviation; SF-MPQ-2, Short-form-McGill Pain Questionnaire-2; STAI, Spielberger’s State Trait Anxiety Inventory; STROBE, Strengthening the Reporting of Observational studies in Epidemiology.

Data Sharing Statement

The datasets generated and analyzed in this work are available for anyone who wishes to access the data by contacting the corresponding author.

Ethics Approval and Informed Consent

The study was approved by the SingHealth Centralized Institutional Review Board, Singapore (SingHealth CIRB Ref: 2014/670/D and 2018/3128) and registered on Clinicaltrials.gov (NCT02278601) on 26 Oct 2014. The authors declare that all the recruited patients provided informed consent, and that this work was conducted in accordance with the Declaration of Helsinki.

Consent for Publication

All patients provided informed consent on the use of their de-identified data for publication purpose.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval for the version to be published; and agreed to be accountable for all aspects of the work.

Acknowledgments

We would like to thank Ms. Agnes Teo (Senior Clinical Research Coordinator), Yvonne Yong (Senior Clinical Research Coordinator), Denise Anne (Clinical Research Coordinator) and Beverly Chia (Research Coordinator) for their administrative support in this work.

Disclosure

All authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by the funding from the National Medical Research Council Clinical Trials Grant - Investigator-Initiated Trials (CTG13feb013). The aforementioned sponsor was not involved in the study activities.